Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 02, 2019 07:30 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics to Present Update at the 2019 HCW Global Life Sciences Conference in London, April 7-9

NEWTOWN, Pa., April 02, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat...
March 26, 2019 07:30 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics, Inc. Reports Business Highlights and Full Year 2018 Financial Results

NEWTOWN, Pa., March 26, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug...
March 25, 2019 07:30 ET | Source: Onconova Therapeutics, Inc.

Onconova Achieves Over 75 Percent of Planned Enrollment in Pivotal Phase 3 INSPIRE Study of Rigosertib in Myelodysplastic Syndromes

Full enrollment of 360 patients anticipated in second half of 2019Pivotal global study continues enrolling worldwide Potential for first new therapy in 15 years to address unmet medical need in MDS ...
March 19, 2019 07:30 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics, Inc. to Provide Corporate Update and Full Year 2018 Financial Results

NEWTOWN, Pa., March 19, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat...
March 12, 2019 07:30 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics, Inc. to Participate at the 31st Annual ROTH Conference March 17-19, 2019 in Orange County, CA

NEWTOWN, Pa., March 12, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat...
February 04, 2019 08:00 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics, Inc. to Present Corporate Update at the BIO CEO & Investor Conference in New York City

NEWTOWN, Pa., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company focused on...
January 31, 2019 07:30 ET | Source: Onconova Therapeutics, Inc.

Advancements in the Treatment of Myelodysplastic Syndromes and RAS-Mutated Lung Cancers to be Presented by Key Opinion Leaders on Thursday, February 7, 2019, in New York City

Invitation-only breakfast event sponsored by Onconova Therapeutics will also be webcast, beginning at 8:00 a.m. EST NEWTOWN, Pa., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc....
January 22, 2019 07:30 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics, Inc. to Present at the NobleCON 15th Annual Investor Conference in Fort Lauderdale, FL

NEWTOWN, Pa., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical stage biopharmaceutical company focused on discovering and developing novel products to...
January 15, 2019 17:15 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics Promotes Dr. Steven M. Fruchtman to Chief Executive Officer

Executive succession plan maintains momentum of recent significant advancesOnconova well-positioned to deliver key milestones in 2019 for both intravenous and oral rigosertib, as well as other...
January 02, 2019 07:30 ET | Source: Onconova Therapeutics, Inc.

Onconova Submits Special Protocol Assessment (SPA) to FDA for Phase 3 Trial of Oral Rigosertib in Combination with Azacitidine (Vidaza®) for First-Line Myelodysplastic Syndromes (MDS)

SPA submitted to the FDA before year-end 2018, marking achievement of a key regulatory milestoneAdvancement of this Phase 3 program, in treatment-naïve higher risk first-line MDS patients, positions...